Home > Research > Publications & Outputs > Multi-arm clinical trials with treatment selection

Research

Associated organisational units

Electronic data

  • cli%2E15%2E13

    Rights statement: This work is licensed under the Creative Commons Attribution-NonCommercial 3.0 Unported License

    Final published version, 1.06 MB, PDF document

    Available under license: CC BY-NC

Links

Text available via DOI:

Keywords

View graph of relations

Multi-arm clinical trials with treatment selection: what can be gained and at what price?

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Multi-arm clinical trials with treatment selection: what can be gained and at what price? / Jaki, Thomas.
In: Clinical Investigation, Vol. 5, No. 4, 04.2015, p. 393-399.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Jaki, T 2015, 'Multi-arm clinical trials with treatment selection: what can be gained and at what price?', Clinical Investigation, vol. 5, no. 4, pp. 393-399. https://doi.org/10.4155/cli.15.13

APA

Jaki, T. (2015). Multi-arm clinical trials with treatment selection: what can be gained and at what price? Clinical Investigation, 5(4), 393-399. https://doi.org/10.4155/cli.15.13

Vancouver

Jaki T. Multi-arm clinical trials with treatment selection: what can be gained and at what price? Clinical Investigation. 2015 Apr;5(4):393-399. doi: 10.4155/cli.15.13

Author

Jaki, Thomas. / Multi-arm clinical trials with treatment selection : what can be gained and at what price?. In: Clinical Investigation. 2015 ; Vol. 5, No. 4. pp. 393-399.

Bibtex

@article{4128030fd22d4bdba3ad030f803ab5b3,
title = "Multi-arm clinical trials with treatment selection: what can be gained and at what price?",
abstract = "With current success rates of confirmatory studies being only around 50%, new approaches to drug development are paramount. Many trials fail simply because ineffective treatments are identified too late. In this paper, we discuss the utility of multi-arm studies with treatment selection as a potential strategy that can reduce the high attrition rate. We illustrate the large gains in efficiency that are possible based on an example in Alzheimer's disease while outlining the additional challenges that need to be overcome to implement such studies.",
keywords = "adaptive design, clinical trial design, multi-arm multi-stage trials, multi-arm trials, treatment selection",
author = "Thomas Jaki",
note = "This work is licensed under the Creative Commons Attribution-NonCommercial 3.0 Unported License",
year = "2015",
month = apr,
doi = "10.4155/cli.15.13",
language = "English",
volume = "5",
pages = "393--399",
journal = "Clinical Investigation",
issn = "2041-6792",
number = "4",

}

RIS

TY - JOUR

T1 - Multi-arm clinical trials with treatment selection

T2 - what can be gained and at what price?

AU - Jaki, Thomas

N1 - This work is licensed under the Creative Commons Attribution-NonCommercial 3.0 Unported License

PY - 2015/4

Y1 - 2015/4

N2 - With current success rates of confirmatory studies being only around 50%, new approaches to drug development are paramount. Many trials fail simply because ineffective treatments are identified too late. In this paper, we discuss the utility of multi-arm studies with treatment selection as a potential strategy that can reduce the high attrition rate. We illustrate the large gains in efficiency that are possible based on an example in Alzheimer's disease while outlining the additional challenges that need to be overcome to implement such studies.

AB - With current success rates of confirmatory studies being only around 50%, new approaches to drug development are paramount. Many trials fail simply because ineffective treatments are identified too late. In this paper, we discuss the utility of multi-arm studies with treatment selection as a potential strategy that can reduce the high attrition rate. We illustrate the large gains in efficiency that are possible based on an example in Alzheimer's disease while outlining the additional challenges that need to be overcome to implement such studies.

KW - adaptive design

KW - clinical trial design

KW - multi-arm multi-stage trials

KW - multi-arm trials

KW - treatment selection

U2 - 10.4155/cli.15.13

DO - 10.4155/cli.15.13

M3 - Journal article

VL - 5

SP - 393

EP - 399

JO - Clinical Investigation

JF - Clinical Investigation

SN - 2041-6792

IS - 4

ER -